Antibiotic maker Tetraphase has announced positive top-line results from the Phase 3 clinical trial of its novel antibiotic, eravacycline, for the treatment of complicated intra-abdominal infections (cIAI). The study (IGNITE 1) showed that eravacycline is as effective as Merck’s antibiotic, ertapenem.
A team of international researchers has made an important discovery that could lead to the development of the first universal dengue vaccine. The researchers, including groups from Australia, Vietnam, and London, have discovered a major new class of antibodies that neutralises all four different types of the deadly dengue virus.
California-based biopharmaceutical company, Auspex Pharmaceuticals, has announced positive topline efficacy and safety results from two phase 3 trials evaluating its investigational drug, SD-809, for the treatment of chorea associated with Huntington's disease (HD)
Researchers at the University of Pittsburgh’s Center for Vaccine Research (CVR) have developed a set of novel antimicrobial peptides that are more effective than traditional antibiotics at fighting different drug-resistant bacteria, including the notorious "superbugs".
California based vaccine maker, PaxVax, has announced positive results from the final Phase 3 trial of its single-dose oral cholera vaccine candidate, PXVX0200.
Massachusetts-based company Cubist Pharmaceuticals has announced that Merck will be acquiring Cubist in a deal valued at about $9.5 billion.
Researchers have found a new class of molecules that is highly potent against the human malaria parasites and causes the parasites’ guts to swell up and explode, CBS News reported.
New York-based radiotherapy company, Actinium Pharmaceuticals, has announced that the US. FDA has granted orphan-drug designation for Actimab-A, an alpha radioisotope-labeled antibody being developed for newly diagnosed AML in patients over the age of 60.
Researchers at the Washington University School of Medicine in St. Louis have developed a new breast cancer vaccine, which has shown promising results in an initial clinical trial
Researchers at the Memorial Sloan Kettering Cancer Centre (MSKCC) in New York have made an important breakthrough in understanding how the body’s immune system recognizes tumor cells, possibly leading to a new generation of improved immunotherapies.
Scientists at the University of Colorado Cancer Center have announced the "extremely promising" results from a phase 1 clinical trial for investigational drug AG-120 in acute myeloid leukemia (AML) patients with IDH1 gene mutations.
Researchers at the National University of Singapore (NUS) have discovered a new type of immune cells that play an important role in multiple sclerosis (MS) and other inflammatory diseases, thus providing a new avenue for therapies for these diseases.
Vienna-based biotech company, Themis Bioscience, has announced the positive results from a phase 1 clinical study of its prophylactic Chikungunya fever vaccine candidate.
New Jersey-based biotech company Celldex Therapeutics has reported the positive interim results from a Phase 2 study of its novel brain cancer immunotherapy vaccine, rindopepimut, in patients with recurrent glioblastoma.
A new coalition of nine charities and funding bodies has been formed to revive the development of promising drug candidates for neurodegenerative brain diseases — an initiative jumpstarted with roughly £30 million ($47 million) in funding.